Evaluation of Polysaccharide Typhim Vi Antibody Response as a predictor of Humoral Immunodeficiency in Haematological Malignancies

An increasing healthcare challenge in the management of haematological malignancy (HM) is secondary immunodeficiency. From January 2019, the EMA included the evaluation of specific antibody (Ab) responses to better select patients for immunoglobulin replacement therapy (IgRT). We evaluated Ab respon...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical immunology (Orlando, Fla.) Fla.), 2020-01, Vol.210, p.108307-108307, Article 108307
Hauptverfasser:	Ochoa-Grullón, J., Benavente Cuesta, C., Pérez López, C., Peña Cortijo, A., Rodríguez de la Peña, A., Álvarez Carmona, A., Mateo Morales, M., Llano-Hernández, K., Williams, L.J., Rodríguez de Frías, E., Guevara-Hoyer, K., Cordero Torres, G., Orte, C., Fernández-Arquero, M., Fernández-Paredes, L., Serrano-García, I., Recio, M.J., Pérez de Diego, R., Martínez, R., Sánchez-Ramón, S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Haematological malignancies Hypogammaglobulinemia Pneumo23 Specific polysaccharide ab response Typhim vi
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!